Avalon Pharmaceuticals, Inc. (Nasdaq:AVRX), today announced, in compliance with NASDAQ Marketplace Rule 4350(b)(1)(B), that the independent audit report included in the Company๏ฟฝs Annual Report on Form 10-K for the fiscal year ended December 31, 2008 contained an unqualified audit opinion from its independent public accounting firm, Ernst & Young LLP, which included a ๏ฟฝgoing concern๏ฟฝ explanatory statement. This disclosure is required under NASDAQ rules and does not represent any change to the Company๏ฟฝs Annual Report on Form 10-K for the year ended December 31, 2008 which was filed on March 31, 2009 with the Securities and Exchange Commission.

About Avalon Pharmaceuticals

Avalon is a biopharmaceutical company focused on the discovery, development and commercialization of first-in-class cancer therapeutics.

Avalon (NASDAQ:AVRX)
๊ณผ๊ฑฐ ๋ฐ์ดํ„ฐ ์ฃผ์‹ ์ฐจํŠธ
๋ถ€ํ„ฐ 4์›”(4) 2024 ์œผ๋กœ 5์›”(5) 2024 Avalon ์ฐจํŠธ๋ฅผ ๋” ๋ณด๋ ค๋ฉด ์—ฌ๊ธฐ๋ฅผ ํด๋ฆญ.
Avalon (NASDAQ:AVRX)
๊ณผ๊ฑฐ ๋ฐ์ดํ„ฐ ์ฃผ์‹ ์ฐจํŠธ
๋ถ€ํ„ฐ 5์›”(5) 2023 ์œผ๋กœ 5์›”(5) 2024 Avalon ์ฐจํŠธ๋ฅผ ๋” ๋ณด๋ ค๋ฉด ์—ฌ๊ธฐ๋ฅผ ํด๋ฆญ.